Loading ...
Sorry, an error occurred while loading the content.

885PR on Lymphocide

Expand Messages
  • Janice and Ben Haines
    Sep 8, 1998
    • 0 Attachment
      For those of you following baseball, did you know this?

      "Roger Maris died of lymphoma, a cancer that attacks the body's lymph
      system, in 1985. He was 51."


      Here is a recent press release on Lymphocide.



      Tuesday September 8, 11:44 am Eastern Time

      Company Press Release

      SOURCE: Immunomedics, Inc.

      Advances Reported with Immunomedics' Antibody Products at International

      Sixteen Papers Presented on Products at the Joint Congress of the European
      Association of Nuclear Medicine and the World Federation of Nuclear
      Medicine and Biology in Berlin, Germany

      MORRIS PLAINS, N.J., Sept. 8 /PRNewswire/ -- Immunomedics, Inc. (Nasdaq:
      IMMU - news) announced today that U.S. and European investigators reported
      on progress with the Company's experimental cancer therapeutics and
      diagnostic imaging agents in over 16 papers presented at this world
      congress held in Berlin last week. The congress was attended by several
      thousand nuclear physicians and other specialists from all parts of the world.

      Cancer Therapy

      CEA-Cide(TM) is being studied by Drs. T. Behr and W. Becker and associates
      at the University of Goettingen Hospital, in Germany, in an ongoing
      dose-escalation trial in patients with colorectal cancer recurrence or
      spread. Among the first 10 patients treated, 2 (20%) have already shown a
      partial response (more than 50% tumor regression), although the optimal
      dose has not yet been achieved. This is consistent with an earlier study
      performed by this German research team, where a 28% objective tumor
      response was found in 40 patients treated with another antibody that
      appears to be less reactive with carcinoembryonic antigen (CEA) than
      CEA-Cide's antibody. Also, the current study uses the humanized version of
      the Company's anti-CEA antibody.

      Results with the Company's LymphoCide(TM) therapeutic for non-Hodgkin's
      lymphoma (NHL) were presented by Dr. J. Tennvall of the University Hospital
      in Lund, Sweden, and by Dr. D.M. Goldenberg of the Garden State Cancer
      Center and Immunomedics, in New Jersey. In advanced NHL patients, including
      those with aggressive forms of this disease, Drs. Tennvall and Goldenberg
      reported that LymphoCide induced major and minor responses as well as
      stabilization in about one-third of the combined total of 18 patients. Dr.
      Goldenberg also reported that the new version of LymphoCide, consisting of
      a humanized anti-CD22 antibody labeled with yttrium-90, a powerful
      therapeutic radionuclide, has already shown partial responses in 2 of the
      first 7 patients studied, all of whom had failed prior chemotherapy and
      having some of the prognostically worst forms of NHL.

      Cancer and Infectious Disease Imaging

      Papers delivered by Dr. V. Ivancevic of the Charite University Hospital in
      Berlin and Dr. S. Gratz of the University of Goettingen Hospital, Germany,
      reported on the usefulness of LeukoScan(R) in the diagnosis of low-grade
      osteomyelitis, especially in patients with prosthetic hip replacement, and
      in patients with arthritis, endocarditis, and atypical appendicitis.

      At the University of Goettingen, Germany, it was found that Immunomedics'
      MyeloScan(TM) product for the detection of cancer spread to the bone
      marrow, which is a prevalent finding in patients with lymphoma, myeloma,
      breast, prostate, and lung cancers, was successful within 30 to 60 minutes
      of being injected. The product consists of the same antibody used in the
      Company's LeukoScan infectious disease imaging product, but in a different
      formulation so as to allow intense and rapid bone marrow imaging. In a
      series of 20 patients studied, it was reported that MyeloScan could reveal
      92% of the cancers that were known to have spread to the bone marrow, with
      additional, previously unknown lesions found in 5 patients.

      Commenting on the success of this congress for the Company, its President
      and Chief Executive Officer, Robert J. DeLuccia, stated: ``We are very
      gratified with the excellent progress reported on our technologies and
      products at this international forum. The therapeutic and imaging products
      under development are moving forward in clinical testing, while the already
      commercialized agents, such as LeukoScan in Europe, are finding more
      clinical applications.''

      Immunomedics is a biopharmaceutical company focused on the development,
      manufacture and commercialization of diagnostic imaging and therapeutic
      products for the detection and treatment of cancer and infectious diseases.
      Integral to these products are highly specific monoclonal antibodies and
      antibody fragments designed to deliver radioisotopes and chemotherapeutic
      agents to tumors and sites of infection. The Company's first product,
      CEA-Scan(R) for the detection of colorectal cancer, has been approved in
      the United States, Canada, and Europe. The Company's second diagnostic
      imaging product, LeukoScan(R), has been approved for sale in Europe for the
      diagnosis of osteomyelitis (bone infection). This product is presently
      under regulatory review by the U.S. Food and Drug Administration.
      Immunomedics also has several other diagnostic imaging products and two
      therapeutic products in clinical trials.

      This release, in addition to historical information, contains certain
      forward-looking statements made pursuant to the Private Securities
      Litigation Reform Act of 1995. Such statements may involve significant
      risks and uncertainties and actual results could differ materially from
      those expressed or implied herein. Factors that could cause such
      differences include, but are not limited to, new product development
      (including clinical trials outcome and regulatory requirement/actions),
      competitive risks to marketed products and availability of financing and
      other sources of capital as well as those discussed in the Company's Annual
      Report on Form 10-K for the year ended June 30, 1997.

      SOURCE: Immunomedics, Inc.